FDA requests further data in order to assess Biologics License Application for teplizumab to delay clinical type 1 diabetes in at risk people

The company have been asked to establish pharmacokinetic (PK) comparability appropriately between their anti-CD3 monoclonal antibody and the clinical trial product or provide other data that adequately justify why PK comparability is not necessary.

Source:

Biospace Inc.